NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $0.07 0.00 (0.00%) As of 10/8/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Sangamo Therapeutics Stock (NASDAQ:SGMO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sangamo Therapeutics alerts:Sign Up Key Stats Today's Range$0.07▼$0.0750-Day Range$0.07▼$0.0752-Week Range$0.06▼$0.77VolumeN/AAverage Volume8.10 million shsMarket Capitalization$30.66 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingReduce Company Overview Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a clinical-stage biotechnology company focused on developing genomic medicines for serious and potentially life-threatening diseases. The company’s research programs address areas including rare genetic disorders, neurological diseases, autoimmune conditions and cancer. Sangamo’s technology platform is based on engineered zinc finger proteins, which can be used to edit DNA, regulate gene expression and develop cell-based therapies. Its pipeline has included in vivo gene therapies, gene-regulation treatments and engineered cell therapies designed to modify disease-related biological pathways. Founded in 1995, Sangamo is headquartered in California and conducts research and development through collaborations with biotechnology and pharmaceutical companies. The company’s programs and partnerships have supported the development of potential treatments for conditions such as Fabry disease, hemophilia and neurological disorders, although many of its therapies remain in clinical development and are not yet approved for broad commercial use.AI Generated. May Contain Errors. Read More Sangamo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreSGMO MarketRank™: Sangamo Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 801st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingSangamo Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 2 sell ratings.Upside PotentialSangamo Therapeutics has a consensus price target of $5.50, representing about 7,332.4% upside from its current price of $0.07.Amount of Analyst CoverageSangamo Therapeutics has received no research coverage in the past 90 days.Read more about Sangamo Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SGMO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.10% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.92% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sangamo Therapeutics' insider trading history. Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGMO Stock News HeadlinesSangamo Therapeutics Completes Fabry Gene Therapy Asset SaleSeptember 21, 2026 | tipranks.comSangamo Therapeutics Advances Bankruptcy Asset Sale ProcessJuly 20, 2026 | tipranks.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Sangamo Therapeutics Inc SGMOJuly 7, 2026 | morningstar.comMSangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and AstellasJune 24, 2026 | markets.businessinsider.comSangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assetsJune 24, 2026 | seekingalpha.comSangamo Therapeutics files for Chapter 11 bankruptcyJune 24, 2026 | msn.comSangamo Therapeutics Initiates Chapter 11 and Asset SalesJune 23, 2026 | tipranks.comSee More Headlines SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $0.42 on January 1st, 2026. Since then, SGMO stock has decreased by 82.4% and is now trading at $0.0740. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Thursday, November, 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.08. The biopharmaceutical company earned $0.58 million during the quarter, compared to the consensus estimate of $34.40 million. Sangamo Therapeutics had a negative net margin of 310.81% and a negative trailing twelve-month return on equity of 2,662.06%. Read the conference call transcript. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), abrdn Asia-Pacific Income Fund (FAX) and Tesla (TSLA). Company Calendar Last Earnings11/06/2025Today10/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SGMO's financial health is in the Red zone, according to TradeSmith. SGMO has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees480Year Founded1995Price Target and Rating Average Price Target for Sangamo Therapeutics$5.50 High Price Target$10.00 Low Price Target$1.00 Potential Upside/Downside+7,332.4%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$122.93 million Net Margins-310.81% Pretax Margin-312.25% Return on Equity-2,662.06% Return on Assets-132.12% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual Sales$39.55 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-1.85Miscellaneous Outstanding Shares414,289,000Free Float397,291,000Market Cap$30.66 million OptionableOptionable Beta1.30 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:SGMO) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMO Stock Alerts